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Abstract Previously, it has been shown that "NO donor S-nitro- 
soglutathione (GSNO) improves the postischemic functional re- 
covery in crystalloid buffer-perfused isolated rat hearts subjected 
to cardioplegic ischemia. Supplementation of cardioplegic solu- 
tion with nitronyl nitroxide, a scavenger of'NO, antagonized this 
protective ffect. Using low temperature ESR, we have detected 
nitrosylmyoglobin (MbNO) in rat hearts subjected to cardiople- 
gic ischemia in the presence of GSNO (20-- 200/zmol/I). During 
aerobic reperfusion MbNO signal intensity gradually decreased, 
but persisted for up to 30 min of aerobic reperfusion. We conclude 
that MbNO is an endogenous marker of "NO release in myocar- 
dial tissues. Implications of MbNO formation are discussed with 
respect to cardioprotection during ischemia- and reperfusion-in- 
duced myocardial injury. 
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I. Introduction 
The current status of the role of nitric oxide ( 'NO) in cardio- 
vascular diseases is controversial [1-5]. Several studies have 
shown that "NO donors protect the heart against ischemia/ 
reperfusion injury in vitro and in vivo animal models [1 3]. In 
other studies [4,5], inhibitors of nitric oxide synthase were 
shown to be beneficial during myocardial ischemia. Using an 
isolated crystalloid buffer-perfused model, we have recently 
shown that supplementation of cardioplegic solution with S- 
nitrosoglutathione (GSNO), a physiologically-relevant "NO 
donor, improved post-ischemic functional recovery [6]. Inter- 
mediacy of "NO was inferred from the antagonistic effects of 
nitronyl nitroxide, an effective scavenger of free "NO [6,7]. 
Cardiac myocytes are enriched with myoglobin, which is 
thought o be involved in the intracellular transport and storage 
of oxygen [8]. Redox cycling of myoglobin has been linked to 
oxidative myocardial damage observed during ischemia and 
reperfusion [9,10]. "NO reacts fairly rapidly with heme-proteins 
(k = 107 M-l.s -j) [11]. Nitrosylmyoglobin (MbNO) formation 
has been shown to mitigate the oxidate damage induced by 
myoglobin [12-14]. Therefore, direct monitoring of MbNO for- 
mation and decay may be critical to understanding its role in 
myocardial injury. 
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The objectives of this study are: (1) to directly demonstrate 
by low-temperature electron spin resonance (ESR) spectros- 
copy the formation of nitrosylmyoglobin heart tissue; and 
(2) to investigate the effect of postischemic reperfusion 
on the formation of MbNO and free radicals in GSNO-treated 
hearts. 
2. Materials and methods 
2.1. Materials 
The nitronyl nitroxide, 2-(p-trimethylammonium)-phenyl-4,4,5,5- 
tetramethyl imidazoline 3-oxide-l-oxyl, was synthesized according to 
published methods [6]. GSNO was prepared according to a procedure 
described by Hart [15]. The authentic MbNO was prepared from 
metmyoglobin (Sigma Chemical Co.) and Angeli's salt as described 
previously [16]. 'Baker analyzed' high purity reagents (JT Baker, Phi- 
lipsburg, N J) were used in perfusion media. All other reagents were 
obtained from Sigma Chemical Co. (St. Louis, MO). 
2.2. Isolated heart perfilsion 
Adult male Sprague-Dawley rats (300-350 g b.wt.), maintained on 
a standard iet, were used for this study. Rats were anesthetized with 
pentobarbital (50 mg/kg b.wt. i.p.) and heparinized via the left femoral 
vein (250 IU/kg). After 1 min, the heart was excised rapidly and placed 
in perfusion medium. Within 30 s, the aorta was attached to a stainless 
steel cannula. The pulmonary artery was incised to permit adequate 
coronary drainage, and the heart was perfused normothermically by the 
method of Langendorff at a perfusion pressure quivalent to 12 kPa 
(90 mmHg). The perfusion medium used was KHB with the following 
composition in mmol/l: NaC1 118.5, NaHCOs 25, KCI 4.8, 
MgSO4.7H20 1.2, KH2PO 4 1.2; and glucose 11.1, in which 
the CaC12-2H20 content was reduced to 1.8 (pH 7.4 when gassed with 
95% 02 and 5% CO2). During preparation of KHB, precautions were 
taken to prevent he precipitation of calcium by gassing the solution 
with 5% CO2. St. Thomas' II solution was used as a cardioplegic 
solution with the following composition i mmol/l: NaC1110, NaHCO 3 
10, KCI 16, MgCI 2 • 6H20 16, and CaCI2 • 2H20 1.2 (pH was titrated to 
7.8 using HC1). 
2.3. Tissue preparation 
After selected intervals of aerobic perfusion, ischemia, and reperfu- 
sion, as shown in section 2.5 (Fig. l), hearts were freeze-clamped be- 
tween stainless steel tongs previously cooled to the temperature of 
liquid nitrogen. Frozen ventricular tissue was then chopped under liq- 
uid nitrogen with a stainless teel spatula to produce small fragments 
(= 2 mm cubes). These fragments were immediately transferred to the 
lumen of a dewar flask that had been precooled to the temperature of
liquid nitrogen. For ESR measurement at liquid helium temperatures, 
the frozen tissue was further chopped into smaller fragments (= 1 mm) 
and inserted into a 4 mm o.d. quartz tube immersed in liquid nitrogen. 
Samples prepared by this technique did not artifactually generate rad- 
ical species [17]. Myocardial tissue homogenate was prepared in ice- 
cold phosphate-buffered saline (25 mmol/1, pH 7.4) using Brinkman 
homogenizer. Immediately after homogenization, tissue homogenate 
was transferred to ESR quartz tubes (4 mm o.d.) and frozen in liquid 
nitrogen. 
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Fig. 1. Experimental protocols. Hatched area in 2 and 3 is 3 min 
perfusion with St. Thomas' II cardioplegic solution (STS) to arrest he 
heart before induction of ischemia. KHB = Krebs-Henseleit buffer. 
2.4. ESR spectroscopy 
ESR spectra from all samples were recorded at liquid nitrogen tem- 
perature with a Varian E-109 spectrometer at 9.5 GHz and 100 kHz 
field modulation. The measurements at 15 K were performed with a 
rectangular TEl02 cavity from Varian. A water warming jacket was used 
to keep the cavity at a constant temperature. Sample temperatures were 
controlled by a Heli-Tran flow system (Allentown, PA) comprised of 
a transfer line and digital indicator/controller and a quartz insert dewar. 
Magnetic field measurements were determined by a using a Radiopan 
M J-110 gaussmeter, and microwave frequency was measured by using 
an EiP 200 frequency counter. The g-values were estimated from meas- 
urement of magnetic field and microwave frequency after correcting for 
the position of the gaussmeter probe. All spectra were obtained by 
signal averaging (5 scans). 
2.5. Experimental protocols 
In protocol 1, hearts were perfused aerobically with KHB at 37°C 
for 20 min. In the GSNO-treated group, hearts were perfused with 
GSNO (200/lmol/l) for 5 min before freeze-clamping. In the ischemia 
protocol, hearts were arrested after 20 rain with a 3 min infusion of St. 
Thomas' II cardioplegic solution at 37°C and subjected to normother- 
mic global ischemia for 10 or 30 min. GSNO (20 or 200 pmol/l) and/or 
nitronyl nitroxide (400 ¢tmol/1) were added to the cardioplegic solution 
immediately before use. After the ischemic period, hearts were freeze- 
clamped and processed for ESR spectroscopy. In separate xperiments, 
hearts were reperfused after 30 min cardioplegic schemia with oxygen- 
ated KHB (which did not contain GSNO) for 2, 20, or 30 rain and then 
freeze-clamped for ESR measurements. 
3. Results 
3.1. Direct detection of nitrosylmyoglobin formation during 
cardioplegic ischemia 
The ESR spectra of control aerobically-perfused and GSNO 
(200 pmol/1)-perfused heart samples are shown in Fig. 2A. The 
spectra reveal the presence of a ubisemiquinone radical 
(g : 2.0045, AHpp = 8.0 + 0.4 G) and a reduced iron-sulfur cen- 
ter (g = 1.94), presumably associated with the mitochondria l  
NADH or succinate dehydrogenase [17,18]. Perfusion with 
GSNO did not alter the ESR spectral pattern (Fig. 2A). The 
ESR spectrum of 10 min ischemic control  heart samples con- 
tained a secondary ubisemiquinone or flavine semiquinone rad- 
ical (g = 2.0045, AHpp = 10 + 0.4 G) along with the reduced 
iron-sulfur center (Fig. 2B). In contrast, the spectrum obtained 
from 10 min ischemic GSNO-treated heart samples showed a 
broad spectrum with anisotropic g-values characteristic of ni- 
trosylmyoglobin (MbNO)  [19]. A broad absorpt ion peak at 
g -- 2.08 is usually observed for MbNO in biological systems. 
The intensity of this signal (marked O) increased with the dura- 
t ion of ischemia (Fig. 2C). Fig. 2D shows the ESR spectrum 
of the sample (i.e. Fig. 2C) at 15 K. The signal-to-noise ratio 
in Fig. 2D was higher as a result of increased Boltzmann factor. 
Furthermore,  the intensity of the ubisemiquinone radical was 
greatly reduced due to power saturat ion of the radical at 15 K. 
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Fig. 2. ESR spectra of (A) control, aerobically perfused (+ GSNO), (B) 
10 rain ischemic (+ GSNO), (C) 30 rain ischemic (+ GSNO) rat heart 
freeze-clamped and chopped at liquid nitrogen temperature prior to 
recording of spectra t 77 K, and (D) same as (C) but spectrum recorded 
at 15 K. Concentration of GSNO was 200tlmo1/1. Symbols: o = semi- 
quinone radical; • = secondary semiquinone; zx= reduced iron-sulfur 
center; and o -- MbNO. Spectrometer conditions used to obtain (A), 
(B), and (C) are: microwave power, 0.2 mW; modulation amplitude, 3.2 
G; gain, 6.3 x 104 scan range, 100 G; scan time, 1 min; time constant, 
0.064 s; microwave frequency, 9.2 GHz. Spectrometer conditions used 
to obtain (D) are: microwave power, 20 mW; modulation amplitude, 
5 G; gain, 2.5 x 104; scan range, 1000 G; scan time, 4 rain; time constant, 
0.128 s; microwave frequency, 9.2 GHz. 





Fig. 3. ESR spectra of (A) homogenized tissue xtract of ischemic heart 
(cf. Fig. 2C) at liquid nitrogen temperature, (B) authentic MbNO ad- 
duct prepared from mixing a 100 #M solution of metmyoglobin with 
100,uM Angeli's alt, and (C) and (D) difference spectra obtained from 
subtracting control (-GSNO) spectrum from (+20 #M GSNO) and 
(+200/aM GSNO) spectrum, respectively. The spike in (C) and (D) 
represents the residual semiquinone signal. [] indicates line position due 
to MbNO. Spectrometer conditions for (A) and (B): microwave power, 
5 mW; modulation amplitude, 3.2 G; gain, 6.3 x 104; scan range, 100 
G; scan time, 1 rain; time constant, 0.064 s; microwave frequency, 9.2 
GHz. 
shown in Fig. 3A. Homogenization f the heart issue at 0-2° C, 
apparently, caused the decay of ubisemiquinone and reduced 
iron-sulfur center signals. The authentic MbNO sample xhib- 
its an ESR spectrum (Fig. 3B) that closely matches the tissue 
spectrum. Figures 3C and D show the difference spectra ob- 
tained from subtracting the control spectrum from 20 and 200 
#M GSNO-treated samples. Based on these ESR results, we 
conclude that myoglobin is an important endogenous intracel- 
lular target for "NO produced from "NO donors in myocardial 
tissue. To prove that MbNO is actually formed from trapping 
of "NO, we investigated the effect of an exogenous "NO scaven- 
ger, nitronyl nitroxide [6,7]. Inclusion of nitronyl nitroxide in- 
hibited the formation of MbNO in GSNO-treated hearts (data 
not shown). 
3.2. Effect of aerobic reperfusion on MbNO signal 
Fig. 4A-C show ESR spectra of aerobically-reperfused 
hearts following 30 min of cardioplegic ischemia. As can be 
seen, control and GSNO-treated hearts (Fig. 4A) reperfused for 
2 min exhibit an increase in the intensity of ubisemiquinone 
radical signal. With increasing reperfusion time, there was a 
decrease in the signal intensity due to both ubisemiquinone and 
MbNO (Fig. 4B and C). Of interest isthe finding that even after 
30 rain of aerobic reperfusion, a significant amount of MbNO 
was still present in the myocardial tissue. Furthermore, the 
presence of GSNO in cardioplegia did not affect he formation 
of the ubisemiquinone radical (Fig. 4A). 
4. Discussion 
The present study demonstrates that formation of MbNO 
can be used as an endogenous intracellular marker of "NO 
released from "NO donors in myocardial tissue. Upon aerobic 
reperfusion, MbNO remains persistent in myocardial tissues, 
but decays gradually with time. Formation of ubisemiquinone 
free radical in reperfused myocardial tissue treated with GSNO 
was unaffected. 
4.1. Mechanism of MbNO formation during ischemia 
Molecular oxygen binds reversibly to the reduced form of 
myoglobin (Mb n) to produce oxymyoglobin (MbII-O2) estab- 
lishing the following equilibrium: (Mb n + 02 ~ MbnO2). Dur- 
ing aerobic perfusion, the most predominant species in myo- 
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Fig. 4. ESR spectra of freeze-clamped and chopped rat hearts aerobi- 
cally reperfused for 2, 20, or 30 rain after 30 min ischemia with or 
without GSNO (200 #moll1). Symbols: © = semiquinone radical; z~ -- 
reduced iron-sulfur center; and [] = MbNO. Spectrometer conditions: 
microwave power, 0.2 mW; modulation amplitude, 3.2 G; gain, 
6.3 × 104; scan range, 100 G; scan time, 1 rain; time constant, 0.064 s; 
microwave frequency, 9.2 GHz. 
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globin (Mb u) accumulates. "NO reacts rapidly with deox- 
ymyoglobin to form nitrosylmyoglobin (MbNO); (Mb" 
+ "NO ~ MbNO). With increasing ischemic duration, the con- 
centration of MbNO in myocardial tissues increases (cf. Fig. 2B 
and C). During aerobic reperfusion, molecular oxygen slowly 
displaces "NO from MbNO (i.e. MbNO + O2~ Mb III 
+ NO3-). This reaction probably accounts for the slow disap- 
pearance of the ESR signal during aerobic reperfusion. The 
exact mechanism of displacement of "NO by 02 is not clear, 
however, this reaction may account for the formation of nitrate 
from "NO in myocardial tissue and effluents during ischemia 
and reperfusion. 
4.2. Implications in cardioprotection and cardiac transplantation 
Arduini et al. [10] have shown that ferrylmyoglobin is formed 
in isolated ischemic heart. They have postulated that fer- 
rylmyoglobin is formed from the reaction between deoxymyo- 
globin and hydrogen peroxide produced uring ischemia. The 
potent oxidizing ability of ferrylmyoglobin has been the sug- 
gested cause of oxidative damage during ischemia nd reperfu- 
sion. In contrast o deoxymyoglobin, MbNO does not react 
with H20 2 to form ferrylmyoglobin. In addition, "NO report- 
edly inhibits H202/myoglobin-induced lipid oxidation [20,21]. 
In other studies, the reaction between protein radical associated 
with ferrylmyoglobin and "NO has been proposed to account 
for the suppression of the peroxidative damage induced by 
myoglobin and hydroperoxides [20-22]. 
ESR spectroscopy has provided irect evidence for increased 
formation o f 'NO during rejection of rat heart allograft. ESR 
spectra of iron-nitrosyl, non-heine nitrosyl, and nitrosylmyo- 
globin were detected in the blood and at the site of allograft 
rejection [23]. Pretreatment with immunosuppressive agents 
greatly decreased the ESR signal. Thus, ESR could be used as 
a sensitive assay to monitor intracellular "NO formation in 
organ transplantation. Recently, it has been shown that cardiac 
preservation can be enhanced in a heterotopic rat model by 
supplementation f heart storage solutions with "NO donors 
[24]. Formation of MbNO during cardiac preservation with 
"NO donors is a distinct possibility. 
The slow displacement o f 'NO from MbNO by oxygen dur- 
ing early reperfusion implies that myoglobin is unable to facil- 
itate intracellular oxygen transport to mitochondria. This has 
been reported to reduce the rate of mitochondrial respiration 
and to elevate the NADH/NAD + ratio [25,26]. Recently, it has 
been shown that GSNO inhibits oxygen consumption by iso- 
lated rat skeletal muscle mitochondria [27]. Reversible inhibi- 
tion of respiration during early reperfusion can contribute to 
the protection of reperfused hearts, since inhibitors of mito- 
chondrial respiration (cyanide and amytal) have been shown to 
reduce mitochondrial Ca 2+ accumulation and intracellular en- 
zyme leakage in reoxygenated myocardium [28,29]. It has been 
hypothesized recently that "NO may be an important physio- 
logical regulator of mitochondrial respiration [30]. Also, as 
mentioned earlier, ferrylmyoglobin formation in reperfused 
myocardial tissues, following ischemia, has been suggested as 
the cause of cardiac dysfunction [10,31]. It is likely that "NO 
donors could inhibit formation of this oxidant, thus protecting 
against he oxidative tissue injury. 
In conclusion, we have shown in this study that ESR moni- 
toring of MbNO can be used as an intracellular marker o f 'NO 
release in muscle tissues. Myoglobin appears to be an 
intracellular trap for nitric oxide. Formation of MbNO may 
contribute to the protective ffects o f 'NO donors in ischemic/ 
reperfused hearts. 
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